DECHRA PHARMACEUTICALS PLC financials
DECHRA PHARMACEUTICALS PLC
213800J4UVB5OWG8VX82 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | £761.5M | £681.8M |
| Cost of sales | £335.2M | £297.0M |
| Gross profit | £426.3M | £384.8M |
| Operating profit (EBIT) | £6.3M | £95.5M |
| Finance costs | £46.0M | £22.3M |
| Profit before tax | -£36.1M | £77.6M |
| Income tax expense | -£8.2M | £19.4M |
| Profit for the year | -£27.9M | £58.2M |
| Total comprehensive income | -£46.0M | £73.5M |
| Per share | ||
| Basic EPS | £-0.25 | £0.54 |
| Diluted EPS | £-0.25 | £0.53 |
| Free cash flow / share | £0.36 | £0.94 |
| Cash flow statement | ||
| Cash generated from operations | £109.3M | £163.3M |
| Net cash from operating activities | £63.6M | £122.9M |
| Income taxes paid | £27.4M | £32.9M |
| Net cash from investing activities | -£426.2M | -£78.3M |
| Purchase of PP&E (capex) | £22.8M | £20.3M |
| Net cash from financing activities | £316.5M | -£46.1M |
| Dividends paid | £51.7M | £44.8M |
| Proceeds from borrowings | £357.4M | £0 |
| Repayments of borrowings | £166.8M | £0 |
| Lease liability payments | £4.3M | £3.6M |
| Net change in cash | -£46.1M | -£1.5M |
| Balance sheet | ||
| Total assets | £1.57B | £1.29B |
| Non-current assets | £1.10B | £848.9M |
| Property, plant & equipment | £159.3M | £100.3M |
| Intangible assets & goodwill | £922.4M | £730.5M |
| Current assets | £467.9M | £444.4M |
| Inventories | £217.3M | £175.7M |
| Trade & other receivables | £161.9M | £136.8M |
| Cash & equivalents | £74.4M | £120.9M |
| Total equity | £755.2M | £666.8M |
| Non-current liabilities | £650.2M | £467.8M |
| Current liabilities | £164.0M | £158.7M |
| Trade & other payables | £144.5M | £136.8M |
| Deferred tax liabilities | £76.3M | £35.8M |
| Derived metrics | ||
| Free cash flow | £40.8M | £102.6M |
| Operating margin | 0.8% | 14.0% |
| Net margin | -3.7% | 8.5% |
| Return on equity | -3.7% | 8.7% |
| Cash conversion ratio | -2.28× | 2.11× |
| Capex coverage | 2.79× | 6.05× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -£31.1M | -£19.3M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -£21.5M | -£23.4M |
| Adjustments For Depreciation Expense | £13.7M | £11.1M |
| Adjustments For Increase Decrease In Trade and Other Payables | -£7.6M | £14.9M |
| Adjustments For Sharebased Payments | -£800.0K | £3.3M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £396.9M | £800.0K |
| Current Tax Assets Current | £14.3M | £11.0M |
| Current Tax Liabilities Current | £11.5M | £12.2M |
| Deferred Tax Assets | £4.9M | £2.3M |
| Dividends Recognised As Distributions To Owners Per Share | £12.50 | £44.89 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£400.0K | £4.0M |
| Finance Income | £4.5M | £5.7M |
| Income Tax Relating To Components of Other Comprehensive Income | £1.1M | £400.0K |
| Increase Decrease Through Sharebased Payment Transactions | £2.2M | £2.9M |
| Increase Decrease Through Transactions With Owners | £132.4M | -£39.6M |
| Increase Decrease Through Transfers and Other Changes Equity | £2.0M | — |
| Interest Received Classified As Investing Activities | £800.0K | £100.0K |
| Investments In Associates Accounted For Using Equity Method | £14.9M | £15.8M |
| Issue of Equity | £182.1M | £2.3M |
| Issued Capital | £1.1M | £1.1M |
| Liabilities | £814.2M | £626.5M |
| Merger Reserve | £84.4M | £84.4M |
| Net Assets Liabilities | £755.2M | £666.8M |
| Net Debt | £430.1M | £208.2M |
| Noncurrent Provisions | £1.7M | £2.2M |
| Other Comprehensive Income | -£18.1M | £15.3M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | -£2.0M | £0 |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -£15.0M | £15.7M |
| Payments For Development Project Expenditure | £2.0M | £1.2M |
| Proceeds From Issuing Shares | £181.9M | £2.3M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | £200.0K | £0 |
| Purchase of Treasury Shares | £200.0K | — |
| Research and Development Expense | £60.8M | £36.1M |
| Reserve of Cash Flow Hedges | £0 | £0 |
| Reserve of Exchange Differences On Translation | -£12.7M | £3.4M |
| Retained Earnings | £86.6M | £164.0M |
| Selling General and Administrative Expense | £359.2M | £253.2M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -£900.0K | -£1.3M |
| Share Premium | £596.0M | £413.9M |
| Treasury Shares | £200.0K | £0 |
Every line item above is a fact tagged in DECHRA PHARMACEUTICALS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.